Artwork

Subhi Saadeh에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Subhi Saadeh 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
Player FM -팟 캐스트 앱
Player FM 앱으로 오프라인으로 전환하세요!

165 - Anatomy of a Target Product Profile(TPP): All 10 Sections EXPLAINED with Marta New

1:10:41
 
공유
 

Manage episode 453617930 series 3325357
Subhi Saadeh에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Subhi Saadeh 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.

In this episode of Let's Combinate, host Subhi Sadeh is joined by Marta New, CEO of Radyus Research, to discuss the importance of Target Product Profiles (TPPs) in drug development and combination products. Marta, with her unique background as a venture capitalist turned CRO founder, shares her insights on how TPPs serve as strategic documents that align clinical goals, regulatory requirements, and market strategies. The discussion delves into the key sections of a TPP, such as target indication, efficacy benchmarks, safety and toxicology, and regulatory strategy. Marta emphasizes the critical role of TPPs in preclinical stages and their impact on the overall success of drug development programs. The episode also explores the integration and collaboration required across various functions like R&D, quality, regulatory, and commercial teams to create and refine a robust TPP.

00:00 Introduction and Welcome

00:26 Meet Marta: CEO of Radius Research

00:58 Understanding Target Product Profiles (TPPs)

01:44 The Importance of TPPs in Drug Development

01:59 Defining a TPP

03:22 TPP as a Strategic Document

05:28 TPP in Preclinical and Clinical Stages

07:09 Challenges and Misconceptions in TPP Development

14:27 Regulatory Considerations for TPPs

14:53 Sections of a TPP

39:07 Understanding Toxicology Evaluations

39:34 FDA Requirements for Pre-IND Talks

39:51 TPP and Toxicity Thresholds

41:41 Go/No-Go Criteria in TPP

42:50 PKPD and Drug Distribution

45:40 Drug Formulation and Quality Attributes

46:36 Regulatory Strategy and 505(b)(2) Pathway

52:34 Differentiation and Risk Assessment

01:03:42 Transition from Discovery to Development

01:07:48 Combination Products and Delivery Systems

01:09:35 Conclusion and Contact Information

Marta New PhD MBA is the CEO of Radyus Research. She is an experienced drug developer with a background in early-stage venture capital, considerable pharma R&D, and university technology transfer. She can be reached at [email protected]

  continue reading

214 에피소드

Artwork
icon공유
 
Manage episode 453617930 series 3325357
Subhi Saadeh에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Subhi Saadeh 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.

In this episode of Let's Combinate, host Subhi Sadeh is joined by Marta New, CEO of Radyus Research, to discuss the importance of Target Product Profiles (TPPs) in drug development and combination products. Marta, with her unique background as a venture capitalist turned CRO founder, shares her insights on how TPPs serve as strategic documents that align clinical goals, regulatory requirements, and market strategies. The discussion delves into the key sections of a TPP, such as target indication, efficacy benchmarks, safety and toxicology, and regulatory strategy. Marta emphasizes the critical role of TPPs in preclinical stages and their impact on the overall success of drug development programs. The episode also explores the integration and collaboration required across various functions like R&D, quality, regulatory, and commercial teams to create and refine a robust TPP.

00:00 Introduction and Welcome

00:26 Meet Marta: CEO of Radius Research

00:58 Understanding Target Product Profiles (TPPs)

01:44 The Importance of TPPs in Drug Development

01:59 Defining a TPP

03:22 TPP as a Strategic Document

05:28 TPP in Preclinical and Clinical Stages

07:09 Challenges and Misconceptions in TPP Development

14:27 Regulatory Considerations for TPPs

14:53 Sections of a TPP

39:07 Understanding Toxicology Evaluations

39:34 FDA Requirements for Pre-IND Talks

39:51 TPP and Toxicity Thresholds

41:41 Go/No-Go Criteria in TPP

42:50 PKPD and Drug Distribution

45:40 Drug Formulation and Quality Attributes

46:36 Regulatory Strategy and 505(b)(2) Pathway

52:34 Differentiation and Risk Assessment

01:03:42 Transition from Discovery to Development

01:07:48 Combination Products and Delivery Systems

01:09:35 Conclusion and Contact Information

Marta New PhD MBA is the CEO of Radyus Research. She is an experienced drug developer with a background in early-stage venture capital, considerable pharma R&D, and university technology transfer. She can be reached at [email protected]

  continue reading

214 에피소드

모든 에피소드

×
 
Loading …

플레이어 FM에 오신것을 환영합니다!

플레이어 FM은 웹에서 고품질 팟캐스트를 검색하여 지금 바로 즐길 수 있도록 합니다. 최고의 팟캐스트 앱이며 Android, iPhone 및 웹에서도 작동합니다. 장치 간 구독 동기화를 위해 가입하세요.

 

빠른 참조 가이드

탐색하는 동안 이 프로그램을 들어보세요.
재생